Pembrolizumab is indicated for the treatment of:

Melanoma:
• Unresectable or metastatic melanoma
• Adjuvant treatment of melanoma with involvement of lymph nodes following complete resection
Non-Small Cell Lung Cancer (NSCLC):
• First-line treatment of metastatic NSCLC with high PD-L1 expression
• In combination with chemotherapy regardless of PD-L1 status
• As a single agent for previously treated metastatic NSCLC
Head and Neck Squamous Cell Carcinoma (HNSCC):
• First-line treatment of metastatic or unresectable recurrent HNSCC
• As monotherapy or in combination with chemotherapy
Classical Hodgkin Lymphoma (cHL):
• Adult and pediatric patients with relapsed or refractory disease
Urothelial Carcinoma:
• Locally advanced or metastatic disease in patients not eligible for cisplatin-containing chemotherapy
• Disease progression during or following platinum-containing chemotherapy
Gastric or Gastroesophageal Junction Adenocarcinoma:
• In combination with chemotherapy for HER2-negative advanced disease
Esophageal Carcinoma:
• Locally advanced or metastatic disease
Cervical Cancer:
• Persistent, recurrent, or metastatic cervical cancer with PD-L1 expression
Hepatocellular Carcinoma (HCC):
• Patients previously treated with sorafenib
Renal Cell Carcinoma (RCC):
• In combination with axitinib for first-line treatment
MSI-H or dMMR Cancer:
• Adult and pediatric patients with unresectable or metastatic solid tumors with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)